FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment von Legry, Vanessa, Descamps, Emeline, Noel, Benoit, Foucart, Corinne, Degallaix, Nathalie, Belanger, Carole, Hum, Dean W., Mégnien, Dr. Sophie, Staels, Prof. Bart, Loomba, Prof. Rohit, Harrison, Prof. Stephen A., Ratziu, Prof. Vlad, Sanyal, Arun J., Walczak, Robert

Volltext

SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH von Hanf, Remy, Chaumat, Pierre, Majd, Zouher, Cordonnier, Genevieve, Brozek, John, Praca, Emilie, Sudrik, Fouad Ben, Bedossa, Prof. Pierre, Anstee, Prof. Quentin M., Francque, Prof. Sven, Harrison, Prof. Stephen A., Ratziu, Prof. Vlad, Mégnien, Sophie, Roudot, Alice, Hosmane, Suneil, Hum, Dean W., Sanyal, Arun J.

Volltext